Prostate apoptosis response-4 (Par-4): an emerging target for Alzheimer’s and Parkinson’s diseases and stroke

Bibliography

• ANTUONO P, BEYER J: The burden of dementia. A medical and research perspective. Theor. Med. Bioeth. (1999) 20:3–13.
   PubMed Web of Science ®Google Scholar
• FISCHER PP: Parkinson's disease and the U.S. health care system. J. CommunityHealth Nurs. (1999) 16:191–204.
   PubMedGoogle Scholar
• SACCO RL, WOLF PA, GORELICK PB: Risk factors and their management for stroke prevention: outlook for 1999 and beyond. Neurology (1999) 53:S15–24.
   PubMedGoogle Scholar
• MATTSON MP: Experimental models of Alzheimer's disease. Science Medicine (1998) 5:16–25.
   Google Scholar
• JENNER P, OLANOW CW: Understanding cell death in Parkinson's disease. Ann. Neurol. (1998) 44:S72–84.
   PubMed Web of Science ®Google Scholar
• DIRNAGL U, IADECOLA C, MOSKOWITZ MA: Pathobi-ology of ischaemic stroke: an integrated view. Trends NeuroscL (1999) 22:391–397.
   PubMed Web of Science ®Google Scholar
• HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99–102.
   PubMed Web of Science ®Google Scholar
• GAMES D, ADAMS D, ALESSANDRINI R: Alzheimer-type neuropathology in transgenic mice overexpressing V717F b-amyloid precursor protein. Nature (1995) 373:523–527.
   PubMed Web of Science ®Google Scholar
• DUFF K, ECKMAN C, ZEHR C: Increased amyloid-b42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 383:710–713.
   PubMed Web of Science ®Google Scholar
• GUO Q, FU W, SOPHER BL: Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knockin mice. Nature Merl. (1999) 5:101–107.
   PubMed Web of Science ®Google Scholar
• STEIN-BEHRENS B, MATTSON MP, CHANG I, YEH M, SAPOLSKY RM: Stress exacerbates neuron loss and cytoskelet al pathology in the hippocampus. NeuroscL (1994) 14:5373–5380.
   PubMed Web of Science ®Google Scholar
• GEULA C, WU CK, SAROFF D, LORENZO A, YUAN M, YANKNER BA: Aging renders the brain vulnerable to amyloid 6-protein neurotoxicity. Nature Merl. (1998) 4:827–831.
   PubMed Web of Science ®Google Scholar
• DUAN W, ZHANG Z, GASH DM, MATTSON MP: Participa-tion of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. (1999) 46:587–597.
   PubMed Web of Science ®Google Scholar
• •Documents association of Par-4 with degeneration of dopaminergic neurones in monkey and mouse models, and demonstrates pivotal role for Par-4 in degeneration of dopaminergic cells.
   Google Scholar
• ENDRES M, FINK K, ZHU J et al.: Neuroprotective effects of gelsolin during murine stroke. J. Clin. Invest. (1999) 103:347–354.
   PubMed Web of Science ®Google Scholar
• KRALL WJ, SRAMEK JJ, CUTLER NR: Cholinesteraseinhibitors: a therapeutic strategy for Alzheimer disease. Ann. Pharmacother. (1999) 33:441–450.
   PubMed Web of Science ®Google Scholar
• PITCHUMONI SS, DORAISWAMY PM: Current status ofantioxidant therapy for Alzheimer's disease. J. Am. Geriatr. Soc. (1998) 46:1566–1572.
   PubMed Web of Science ®Google Scholar
• SHERWIN BB: Hormones, mood, and cognitive functioning in postmenopausal women. Obstet. Gynecol. (1996) 87:20S–26S.
   Google Scholar
• TANG MX, JACOBS D, STERN Y et al.: Effect of oestrogenduring menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 348:429–432.
   PubMed Web of Science ®Google Scholar
• SHOULSON I: DATATOP: A decade of neuroprotectiveinquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neurol. (1998) 44:S160–166.
   PubMed Web of Science ®Google Scholar
• KWIATKOWSKI TG, LIBMAN RB, FRANKEL M et al.: Effectsof tissue plasminogen activator for acute ischemic stroke at one year. National institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke study group. N Engl. J. Merl. (1999) 340:1781–1787.
   PubMed Web of Science ®Google Scholar
• KASTE M, FOGELHOLM R, ERILA T: A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 25:1348-1353.
   Google Scholar
• MUIR KW, GROSSET DG, GAMZU E, LEES KR: Pharma-cological effects of the non-competitive NMDA antago-nist CNS1102 in normal volunteers. Br. J. PharmacoL (1994) 38:33–38.
   Web of Science ®Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K: Ebselen in acuteischemic stroke: a clinical placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke (1998) 29:12–17.
   PubMed Web of Science ®Google Scholar
• SOHAL RS, WEINDRUCH R: Oxidative stress, caloricrestriction, and aging. Science (1996) 273:59–63.
   PubMed Web of Science ®Google Scholar
• BRUCE-KELLER AJ, UMBERGER G, MCFALL R, MATTSONMP: Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann. Neurol (1999) 45:8–15.
   PubMed Web of Science ®Google Scholar
• ZHU H, GUO Q, MATTSON MP: Dietary restrictionprotects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res. (1999) 842:224–229.
   PubMed Web of Science ®Google Scholar
• DUAN W, MATTSON MP: Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. NeuroscL Res. (1999) 57:195–206.
   PubMed Web of Science ®Google Scholar
• YU Z, MATTSON MP: Dietary restriction and2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J. NeuroscL Res. (1999) 57:830–839.
   PubMed Web of Science ®Google Scholar
• MAYEUX R, COSTA R, BELL K, MERCHANT C, TUNG MX, JACOBS D: Reduced risk of Alzheimer's disease among individuals with low calorie intake. Neurology (1999) 59:S296–297.
   Google Scholar
• LOGROSCINO G, MARDER K, COTE L, TANG MX, SHEA S, MAYEUX R: Dietary lipids and antioxidants in Parkin-son's disease: a population-based, case-control study. Ann. Neurol (1996) 39:89–94.
   PubMed Web of Science ®Google Scholar
• SANO M, ERNESTO C, THOMAS RG et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The AD Coopera-tive Study. N Engl. J. Med. (1997) 336:1216–1222.
   PubMed Web of Science ®Google Scholar
• MORRIS MC, BECKETT LA, SCHERR PA: Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Ann. Neurol. (1998) 43:452–457.
   PubMed Web of Science ®Google Scholar
• FOY CJ, PASSMORE AP, VAHIDASSR MD, YOUNG IS, LAWSON JT: Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkin-son's disease. Quart. J. Med. (1999) 92:39–45.
   Google Scholar
• MCGEER EG, MCGEER EL: The importance of inflamma-tory mechanisms in Alzheimer's disease. Exp. Gerontol. (1998) 33:371–378.
   PubMed Web of Science ®Google Scholar
• HART RG, BEN VENTE 0: Stroke: part I. A clinical update on prevention. Am. Fain. Physician (1999) 59:2475–2482.
   PubMed Web of Science ®Google Scholar
• AUBIN N, CURET O, DEFFOIS A, CARTER C: Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. (1998) 71:1635–1642.
   PubMed Web of Science ®Google Scholar
• SELLS SF, WOOD DP, JOSHI-BARVE SS: Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and-independent prostate cells. Cell Growth Differ. (1994) 5:457–466.
   PubMedGoogle Scholar
• •Seminal study describing identification and cloning of Par-4.
   Google Scholar
• SELLS SF, HAN SS, MUTHUKKUMAR S: Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol. Cell. Biol. (1997) 17:3823–3832.
   PubMed Web of Science ®Google Scholar
• GUO Q, FU W, XIE J: Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Nature Med. (1998) 4:957–962.
   PubMed Web of Science ®Google Scholar
• ••Establishes association of Par-4 with neuronal degenerationin Alzheimer's disease, and demonstrates pivotal role for Par-4 in degeneration of neurones in genetic and experi-mental models of Alzheimer's disease.
   Google Scholar
• BOGHAERT ER, SELLS SF, WALID AJ et al.: Immunohisto-chemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ. (1997) 8:881–890.
   PubMedGoogle Scholar
• CHAN SL, TAMMARIELLO SP, ESTUS S, MATTSON MP: Par-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J. Neurochem. (1999) 73:502–512.
   PubMed Web of Science ®Google Scholar
• DUAN W, ZHANG Z, GASH DM, MATTSON MP: Participa-tion of Par-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. (1999) 46:587–597.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE RW, TOMMERUP N, HANSEN C, VISSING H, SHI Y: Mapping of the human PAWR (par-4) gene to chromosome 12q21. Genomics (1998) 53:241–243.
   PubMed Web of Science ®Google Scholar
• PEDERSEN WA, LUO H, FU W et al. Evidence that Par-4 participates in motor neuron death in amyotrophic lateral sclerosis. FASEB (2000) (In Press)
   PubMedGoogle Scholar
• DUAN W, GUO Z, MATTSON MP: Participation of Par-4 in the degeneration of striatal neurons in a rat model of Huntington's disease. Exp. Neurol (2000) (In Press).
   PubMedGoogle Scholar
• MATTSON MP, KELLER JN, BEGLEY JG: Evidence for synaptic apoptosis. Exp. Neurol. (1998) 153:35–48.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, PARTIN J, BEGLEY JG: Amyloid b-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. (1998) 807:167–176.
   PubMed Web of Science ®Google Scholar
• DUAN W, RANGNEKAR V, MATTSON MP: Par-4 produc-tion in synaptic compartments following apoptotic and excitotoxic insults: evidence for a pivotal role in mitochondrial dysfunction and neuronal degenera-tion. J. Neurochem. (1999) 72:2312–2322.
   PubMed Web of Science ®Google Scholar
• •First demonstration of translational regulation of an apoptotic gene product in synaptic terminals, and establishes a role for Par-4 in apoptosis-related synaptic mitochondrial dysfunction.
   Google Scholar
• MATTSON MP: Cellular actions of b-amyloid precursor protein, and its soluble and fibrillogenic peptide derivatives. Physiol. Rev. (1997) 77:1081–1132.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, CHENG B, DAVIS D, BRYANT K, LIEBER-BURG I, RYDEL RE: b-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. (1992) 12:376–389.
   PubMed Web of Science ®Google Scholar
• MARK RJ, HENSLEY K, BUTTERFIELD DA, MATTSON MP:Amyloid 0-peptide impairs ion-motive ATPase activi-ties: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. (1995) 15:6239–6249.
   PubMed Web of Science ®Google Scholar
• KRUMAN I, BRUCE-KELLER AJ, BREDESEN DE, WAEG G, MATTSON MP: Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. j Neurosci. (1997) 17:5089–5100.
   PubMed Web of Science ®Google Scholar
• GUO Q, FURUKAWA K, SOPHER BL et al.: Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid b-peptide. NeuroReport (1996) 8:379–383.
   PubMed Web of Science ®Google Scholar
• GUO Q, SOPHER BL, PHAM DG et al.: Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid 0-peptide: involvement of calcium and oxyradicals. j Neurosci. (1997) 17:4212–4222.
   Web of Science ®Google Scholar
• GUO Q, SEBASTIAN L, SOPHER BL et al.: Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid b-peptide toxicity: central roles of superoxide produc-tion and caspase activation. J. Neurochem. (1999) 72:1019–1029.
   PubMed Web of Science ®Google Scholar
• GUO Q, FU W, SOPHER BL et al.: Increased vulnerabilityof hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knockin mice. Nature Med. (1999) 5:101–107.
   PubMed Web of Science ®Google Scholar
• GUO Q, SEBASTIAN L, SOPHER BL et al. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a presenilin-1 mutation. Proc. Natl. Acad. ScL USA (1999) 96:4125–4130.
   PubMed Web of Science ®Google Scholar
• JENNER P, OLANOW CW: Understanding cell death in Parkinson's disease. Ann. Neurol. (1998) 44:S72–84.
   PubMed Web of Science ®Google Scholar
• SCHAPIRA AH, GU M, TAANMAN JW: Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol (1998) 44:S89–98.
   PubMed Web of Science ®Google Scholar
• BANDMAN O, MARSDEN CD, WOOD NW: Genetic aspects of Parkinson's disease. Mov. Disord. (1998) 13:203–211.
   PubMed Web of Science ®Google Scholar
• LANGSTON JW: Epidemiology versus genetics inParkinson's disease: progress in resolving an age-old debate. Ann. Neurol. (1998) 44:S45–S52.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI H, GOTO K, MORI H, MIZUNO Y: Histochemical detection of apoptosis in Parkinson's disease. J. Neurol ScL (1996) 137:120–123.
   PubMed Web of Science ®Google Scholar
• PETERSEN A, MANI K, BRUNDIN P: Recent advances on the pathogenesis of Huntington's disease. Exp. Neurol. (1999) 157:1–18.
   PubMed Web of Science ®Google Scholar
• INCE PG, LOWE J, SHAW PJ: Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol. Appl. Neurobiol. (1998) 24:104–117.
   PubMed Web of Science ®Google Scholar
• BEAL MF: Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol. (1994) 7:542–547.
   PubMed Web of Science ®Google Scholar
• CULMSEE C, KRIEGLSTEIN J, MATTSON MP: Participationof of Par-4 in selective neuronal degeneration induced by transient focal and global cerebral ischemia. J. Cereb. Blood Flow Metab. (2000) (Submitted).
   Google Scholar
• DIAZ-MECO MT, MUNICIO MM, FRUTOS S et al.: The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell (1996) 86:777–786.
   PubMed Web of Science ®Google Scholar
• •Identifies protein kinase C as a protein that interacts with Par-4, and provides evidence that this interaction is involved in the pro-apoptotic function of Par–4.
   Google Scholar
• FRUTOS S, MOSCAT J, DIAZ-MECO MT: Cleavage of zetaPKC but not lambda/iotaPKC by caspase-3 during UV-induced apoptosis. J. Biol. Chem. (1999) 274:10765–10770.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE RW, SEE RH, SELLS SF et al.: A novel repressor, Par-4, modulates transcription and growth suppression functions of the Wilms tumor suppressor WT1. Mol Cell. Biol. (1996) 16:6945–6956.
   PubMed Web of Science ®Google Scholar
• BERRA E, MUNICIO MM, SANS L, FRUTOS S, DIAZ-MECO MT, MOSCAT J: Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade. Mol. Cell. Biol. (1997) 17:4346–4354.
   PubMed Web of Science ®Google Scholar
• PULS A, SCHMIDT SS, GRAWE F, STABEL S: Interaction ofprotein kinase C zeta with ZIP, a novel protein kinase C-binding protein. Proc. Natl. Acad. ScL USA (1997) 94:6191–6196.
   PubMed Web of Science ®Google Scholar
• MENKE AL, VAN DER EB AJ, JOCHEMSEN AG: The Wilmstumor 1 gene: oncogene or tumor suppressor gene? Int. Rev. Cytol. (1998) 181:151–212.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG JF, PRITCHARD-JONES K, BICKMORE WA, HASTIE ND, BARD JB: The expression of the Wilms tumour gene, WT1, in the developing mammalian embryo. Mech. Dev. (1993) 40:85–97.
   PubMed Web of Science ®Google Scholar
• BARGER SW, HORSTER D, FURUKAWA K, GOODMAN Y, KRIEGLSTEIN J, MATTSON MP: Tumor necrosis factors a and 13 protect neurons against amyloid 0-peptide toxicity: evidence for involvement of a KB-binding factor and attenuation of peroxide and Ca2+ accumula-tion. Proc. Natl. Acad. Sci. USA (1995) 92:9328–9332.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, GOODMAN Y, LUO H, FU W, FURUKAWA K: Activation of NF-KB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of Mn-SOD and suppression of peroxyni-trite production and protein tyrosine nitration. J. Neurosci. Res. (1997) 49:681–697.
   PubMed Web of Science ®Google Scholar
• FURUKAWA K, MATTSON MP: The transcription factor NF-KB mediates increases in calcium currents and decreases in NMDA and AMPA/kainate-induced currents in response to TNFa in hippocampal neurons. J. Neurochem. (1998) 70:1876–1886.
   PubMed Web of Science ®Google Scholar
• DEVERAUX QL, REED JC: Inhibitor of apoptosis proteins (IAPs). In: Programmed Cell Death. Vol. 1. Mattson MP, Rangnekar V, Estus S (Eds.), JAI Press, Greenwich, CT, USA (2000) (In Press).
   Google Scholar
• CHENG B, CHRISTAKOS S, MATTSON MP: Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron (1994) 12:139–153.
   PubMed Web of Science ®Google Scholar
• ANRATHER J, CSIZMADIA V, SOARES MP, WINKLER H:Regulation of NF-KB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Cz in primary endothelial cells. J. Biol. Chem. (1999) 274:13594–13603.
   PubMed Web of Science ®Google Scholar
• CAMANDOLA S, MATTSON MP: The pro-apoptotic action of Par-4 involves inhibition of NF-icB activity and suppression of Bc1-2 expression. J. Neurosci. Res. (2000) (Submitted).
   PubMedGoogle Scholar
• CHAN SL, MATTSON MP: Caspase and calpain substrates: roles in synaptic plasticity and cell death. J. Neurosci. Res. (1999) 58:167–190.
   PubMed Web of Science ®Google Scholar
• SANCHEZ I, XU C, JUO J, KAKIZAKA A, BLENIS J, YUAN J:Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron (1999) 22:623–633.
   PubMed Web of Science ®Google Scholar
• GUO Q, CHAN SL, KRUMAN I: The Bc1-2 family ofproteins and their actions within the molecular machinery of cell death. In: Programmed Cell Death. Vol. 1. Mattson MP, Rangnekar V, Estus S (Eds.), JAI Press, Greenwich, CT, USA (2000) (In Press).
   Google Scholar
• CHAN SL, MATTSON MP: Par-4 interacts with Bc1-2 and is translocated to mitochondria during apoptosis of pheochromocytoma cells. J. Neurosci. (2000) (Submitted).
   Google Scholar
• BRUCE-KELLER AJ, BEGLEY JG, FU W et al.: Bc1-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid 0-peptide. J. Neurochem. (1997) 70:31–39.
   Web of Science ®Google Scholar
• TAMATANI M, CHE YH, MATSUZAKI H et al.: Tumornecrosis factor induces bc1-2 and bcl-x expression through NEKB activation in primary hippocampal neurons. J. Biol. Chem. (1999) 274:8531–8538.
   PubMed Web of Science ®Google Scholar
• QIU G, AHMED M, SELLS SF, MOHIUDDIN M, WEINSTEINMH, RANGNEKAR VM: Oncogene Mutually exclusive expression patterns of Bc1-2 and Par-4 in human prostate tumors consistent with down-regulation of Bc1-2 by Par-4. Oncogene (1999) 18:623–631.
   PubMed Web of Science ®Google Scholar
• TREMBLAY R, HEWITT K, LESIUK H, MEALING G, MORLEY P, DURKIN JP: Evidence that brain-derived neurotrophic factor neuroprotection is linked to its ability to reverse the NMDA-induced inactivation of protein kinase C in cortical neurons. J. Neurochem. (1999) 72:102–111.
   PubMed Web of Science ®Google Scholar
• MATTSON MP: Neuroprotective signal transduction: relevance to stroke. Neurosci. Biobehav. Rev. (1996) 21:193–206.
   Web of Science ®Google Scholar
• BRADFORD HF, ZHOU J, PLIEGO-RIVERO B, STERN GM, JAUNIAUX E: Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease. Adv. Neurol. (1999) 80:19–25.
   PubMedGoogle Scholar
• MATSUMOTO S, FRIBERG H, FERRAND-DRAKE M, WIELOCH T Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. (1999) 19:756–741.
   Google Scholar
• SCHULZ JB, WELLER M, MOSKOWITZ MA: Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neurol (1999) 45:421–429.
   PubMed Web of Science ®Google Scholar
• KELLER JN, GUO Q, HOLTSBERG FW, BRUCE-KELLER AJ, MATTSON MP: Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and oxyradical production. J. Neurosci. (1998) 18:4439–4450.
   PubMed Web of Science ®Google Scholar
• CHAN SL, GRIFIN WS, MATTSON MP: Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. J. Neurosci. Res. (1999) 57:315–323.
   PubMed Web of Science ®Google Scholar
• CUTILLAS B, ESPEJO M, GIL J, FERRER I, AMBROSIO S: Caspase inhibition protects nigral neurons against 6-0HDA-induced retrograde degeneration. NeuroRe-port (1999) 1:2605–2608.
   Google Scholar
• MATTHEWS RT, FERRANTE RJ, KLIVENYI P et al.: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. (1999) 157:142–149.
   PubMed Web of Science ®Google Scholar